Company intelligence / Profile preview

MedImprove

Ownership: Private
Development stage: Commercial

Overview

MedImprove is an active multidisciplinary medical center specializing in respiratory revalidation. It employs innovative imaging techniques developed by Fluidda to personalize treatment for patients with chronic lung diseases, including severe COPD and long COVID. The approach combines advanced diagnostics with tailored exercise rehabilitation, oxygen therapy, and pharmacological treatments. Clinical experience suggests most patients show significant health improvement within three months of starting the program[1][5].

Therapeutic areas: Pulmonology
Modalities: Non-pharmacological therapyDevice (imaging technology)Exercise rehabilitationOxygen therapy
Industry: Non-Academic Healthcare

Partnerships

Fluidda (technology partner; provides proprietary FRI imaging technology)

Beyond the preview

Go deeper on MedImprove.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedImprove.

Explore the full profile